Últimas noticias sobre Passage Bio (NASDAQ:PASG) Bolsa

PASSAGE BIO INC

Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Passage Bio Inc

JP Morgan analyst Reginald Smith maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Overweight and lowers the price target from $124 to $115.

News

Price Target

Analyst Ratings

SHOP

JP Morgan Maintains Overweight on Shopify, Lowers Price Target to $115

The <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">April U.S. employment report </a>brought a welcome economic balancing act. Nonfarm payrolls increased by 177,000, beating comfortably the 130,000 forecast by economists and almost doubling the 90,000 predicted by Kalshi betting markets. 
Average hourly earnings, however, slowed to 0.2% month-over-month from 0.3% in March, barely missing consensus forecasts.
The outcome? A tight labor market without overheating provides the Federal Reserve and markets a bit more room to breathe. For the financial sector in particular, an unusually favorable balance of stability and opportunity has emerged from the current conditions.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45328557/targets-self-checkout-flip-flop-isnt-helping-after-a-66-value-crash-are-retail-etfs-ringing-up-t">Target&#8217;s Self-Checkout Flip-Flop Isn&#8217;t Helping After A 66% Value Crash: Are Retail ETFs Ringing Up The Real Risk?</a>
<h1 class="wp-block-heading">ETF Watch: Who Wins?</h1>
With job growth still being maintained but wage pressures dissipating, a number of <a href="https://www.benzinga.com/etfs">financial sector ETFs</a> may ride the macro tailwinds:
Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)
The heavyweight of financial ETFs, XLF follows blue-chip stocks such as JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), and Goldman Sachs Group Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>). Sectoral employment growth in financial activities (continued growth in April) indicates underlying strength, and subdued wage growth increases profitability and cools inflation risk, a net benefit to big banks with wide exposure.
SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>) Thie ETF provides equal-weighted exposure to large as well as regional banks. With the slower wage growth, consumer spending might be hit, forcing prices down (read: inflation). The Fed might consider continuing the pause, or even turn back on, rate increases. Regional banks could feel the boost of a rebound in loan demand and reduced funding costs.
Invesco KBW High Dividend Yield Financial ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWD#NASDAQ">KBWD</a>) This ETF has a tilt toward high-yielding financials such as REITs and business development companies. Lower inflation expectations render its dividend-rich holdings more appealing in real terms, while decelerating wage inflation contributes to supporting payout sustainability.
<h1 class="wp-block-heading">Why This Labor Market Arrangement Works For Financials</h1>
The market response isn&#8217;t all about employment numbers, it&#8217;s about the &#8220;goldilocks&#8221; combination they generate.
<ul class="wp-block-list">
<li>Reduced Inflation Expectations: Slower wage growth typically means softer consumer spending, which then lowers inflationary pressure. That&#8217;s a good thing for banks, which rely on stable inflation to inform lending decisions and determine interest rate margins.</li>
<li>More Favorable Rate Outlook: If the Fed perceives wages moderating, it might delay further rate increases, or even begin lowering them. For banks, declining interest rates can fuel a flood of new consumer debt, mortgage requests and corporate loans — the stuff of bank profits.</li>
<li>Firming Corporate Margins: Slower wage growth equals lower input costs. That&#8217;s a good thing for banks, and any financial institution with exposure to corporate bonds or equity markets, too. Higher margins lower credit risk and increase investment returns.</li>
<li>Lower Labor Costs: Yes, even the financial industry experiences wage pressure. With labor expenses stabilizing, internal margins rise, providing CFOs and asset managers with more room to breathe. </li>
</ul>
The Macro Signal: Stability Without Stagnation
April&#8217;s figures indicate a labor market that&#8217;s strong in all the right areas. Health care, transportation, and finance created jobs, while government payrolls declined as it restructures. The unemployment rate remained at 4.2%, indicating labor demand remains robust, even as the Fed&#8217;s inflation battle slows the wage engine.
For investors, it is time to re-examine where the smart money goes next. With an economy that continues to grow but inflation retrenches, financial ETFs might be quietly positioning for outperformance — particularly those well-situated to profit from increasing credit activity, more stable margins, and leaner labor expenses.
The market did not roar following the jobs report — but it did not need to. For financials, a subtle beat might reverberate louder than any rally.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45297474/imtm-etf-tanks-then-soars-why-global-momentum-is-making-a-comeback">IMTM ETF Tanks, Then Soars: Why Global Momentum Is Making A Comeback</a></li>
</ul>
Photo: NicoElNino via Shutterstock.com

Sector ETFs

ETFs

KBWD

Jobs Up, Wages Down: Financial ETFs May Have Just Found Their Sweet Spot

JP Morgan analyst Samik Chatterjee maintains Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Neutral and raises the price target from $20 to $21.

INGM

JP Morgan Maintains Neutral on Ingram Micro Holding, Raises Price Target to $21

Network-1 Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NTIP#AMEX">NTIP</a>) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year. The company reported $150.00 thousand in sales this quarter.

Earnings

NTIP

Network-1 Technologies Q1 EPS $(0.02) Up From $(0.04) YoY, Sales $150.00K

JP Morgan analyst Kenneth Worthington maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Neutral and lowers the price target from $276 to $215.

COIN

JP Morgan Maintains Neutral on Coinbase Global, Lowers Price Target to $215

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 10 years by 24.19% on an annualized basis producing an average annual return of 34.47%. Currently, Comfort Systems USA has a market capitalization of $15.34 billion. 
Buying $1000 In FIX: If an investor had bought $1000 of FIX stock 10 years ago, it would be worth $19,536.39 today based on a price of $434.88 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746823514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

General

FS KKR Capital Enters Equity Distribution Agreements; Agreements Allow Sale Of Up To $750M In Stock

JP Morgan analyst Jeffrey Zekaukas maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Overweight and raises the price target from $29 to $35.

JP Morgan Maintains Overweight on Mosaic, Raises Price Target to $35

JP Morgan analyst Christopher Horvers maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $140 to $105.

JP Morgan Maintains Neutral on Target, Lowers Price Target to $105

Offerings

ADAG

Adagene Files For Mixed Shelf Of Up To $200M

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Overweight and lowers the price target from $45 to $44.

RCKT

JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Lowers Price Target to $44

PSQH

PSQ Holdings Files For Mixed Shelf Of Up To $200M

JP Morgan analyst Cory Carpenter maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $29 to $28.

MTCH

JP Morgan Maintains Neutral on Match Group, Lowers Price Target to $28

WULF

Terawulf May Offer & Sell Shares Of Common Stock, From Time To Time, Of Up To $200M Through Or To Applicable Agent

MEGL

Magic Empire Global Files Prospectus For Offer And Sale Of Up To 15M Class A Shares

JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Underweight and lowers the price target from $9 to $7.

NVAX

JP Morgan Maintains Underweight on Novavax, Lowers Price Target to $7

ACAD

ACADIA Pharmaceuticals Files For Offering Of Up To 43.6M Shares Of Common Stock By The Selling Stockholders

Biotech

Events

Rocket Pharmaceuticals To Present Phase 1 Clinical Trial Of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of American Society Of Gene And Cell Therapy

JP Morgan analyst Ryan Brinkman maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Overweight and raises the price target from $119 to $120.

JP Morgan Maintains Overweight on Lear, Raises Price Target to $120

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.11% on an annualized basis producing an average annual return of 12.39%. Currently, Danaher has a market capitalization of $135.78 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $323.32 today based on a price of $189.73 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746822613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Press Releases

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Health Care

Management

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Comments

Passage Bio

Noticias

Últimas noticias sobre Passage Bio (NASDAQ:PASG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL